New clinical trials with vitamin D and analogs in renal disease  by Kumar, Rajiv
see original article on page 841
see original article on page 851
commentar yhttp://www.kidney-international.org
© 2011 International Society of Nephrology
Kidney International (2011)  80    793
 Vitamin D metabolites such as 1  ,25-dihy-
droxyvitamin D (1  ,25(OH) 2 D 3 , calci-
triol) and vitamin D analogs (such 
as paricalcitol) are recommended and fre-
quently used for the treatment of renal 
osteodystrophy and secondary hyperpara-
thyroidism seen in the context of chronic 
renal failure and end-stage renal disease 
(ESRD). 1,2 Th e mechanisms by which vita-
min D analogs, especially the 1  -hydroxy-
lated metabolite, 1  ,25(OH) 2 D 3 ( Figure 
1 ), regulate parathyroid hormone (PTH) 
concentrations include an increase in 
serum calcium, which occurs as a result of 
enhanced intestinal calcium absorption, 
enhanced bone calcium resorption, and an 
inhibition of  PTH gene transcription. 3 
Because vitamin D analogs increase serum 
calcium and inorganic phosphate concen-
trations by increasing intestinal absorption 
and bone resorption of these substances, 4 
and since elevated serum inorganic phos-
phorus concentrations and an elevated 
serum calcium  × inorganic phosphate 
product are associated with cardiovascular 
disease and mortality 5 in ESRD, therapy 
for secondary hyper parathyroidism in 
ESRD patients with vitamin D analogs is 
instituted after control of hyperphos-
phatemia, usually by a combination of 
dietary measures and treatment with 
phosphate binders. It would be of value for 
vitamin D analogs to have a prefe rential 
eff ect on  PTH gene transcription without 
enhancing intestinal calcium and phos-
phate absorption or bone mineral resorp-
tion, and it is possible to envisage 
inhibition of  PTH gene tran s cription by 
vitamin D analogs without concomitant 
increases in serum calcium (and inorganic 
phosphorus) concentrations due to 
increased intestinal calcium (and phos-
phorus) absorption or bone mineral 
resorption. Indeed, a vitamin D 2 analog, 
paricalcitol ( Figure 1 , inset), has been 
shown to exhibit such properties inasmuch 
as it decreases PTH concentrations with-
out substantially increasing serum con-
centrations of calcium and phosphorus in 
partially nephrectomized rats and in 
humans with ESRD. 6,7 In these studies, 
1  ,25(OH) 2 D 3 (calcitriol) was eff ective in 
reducing PTH concentrations but caused 
more hypercalcemia and hyperphos-
phatemia than paricalcitol. Furthermore, 
less arterial calcification was noted in 
nephrectomized rats given paricalcitol 
than in rats given calcitriol, 8 suggesting 
that cardiovascular mortality would be 
lower in the paricalcitol-treated animals. 
Th ese studies have been extrapolated to 
humans with ESRD, and as a result, pari-
calcitol is widely used in the treatment of 
secondary hyperparathyroidism in 
patients with ESRD. 
 In a very interesting paper published in 
this issue of  Kidney International , Hansen 
 et al. 9 demonstrate that a vitamin D ana-
log, alfacalcidol (1  -hydroxyvitamin D 3 ; 
 Figure 1 ), which is metabolized to 
1  ,25(OH) 2 D 3 by the hepatic 25-hydroxy-
lase enzyme, and which is widely used in 
Europe for the treatment of secondary 
hyperparathyroidism, is as effective as 
paricalcitol in reducing PTH concentra-
tions. Furthermore, alfacalcidol causes no 
more hypercalcemia or hyperphos-
phatemia than paricalcitol. Th ese authors 
conducted a randomized crossover trial 
in 86 ESRD patients, who received 
increasing doses of alfacalcidol or parical-
citol for 16 weeks until PTH concentra-
tions were adequately suppressed or 
calcium or phosphate concentrations 
reached an upper threshold. After a 
2-week  ‘ washout ’ period, subjects who were 
initially on alfacalcidol were placed on 
paricalcitol, and those initially on parical-
citol were placed on alfacalcidol, and the 
trial was continued for another 16 weeks. 
The proportion of patients achieving a 
30 % decrease in PTH concentrations over 
the last 4 weeks of period 1 was similar in 
the paricalcitol-treated and alfacalcidol-
treated groups. Surprisingly, alfacalcidol 
did not cause substantial hypercalcemia or 
hyperphosphatemia at doses suffi  cient to 
decrease PTH concentrations by 30 % , and 
hypercalcemia and hyperphosphatemia 
were similar in the alfacalcidol- and pari-
calcitol-treated groups in the fi rst period 
of the study. The study appeared to be 
adequately powered to detect a 20 % diff er-
ence in PTH concentrations between the 
two treatment groups with an 86 % power. 
However, because of a period eff ect, only 
data from the fi rst period were analyzed, 
which is somewhat disappointing, as it 
would have been interesting to know 
whether diff erences in PTH, calcium, and 
phosphorus concentrations were present 
in the groups treated with two diff erent 
vitamin D analogs for a longer time. Addi-
tional analyses demonstrated that parical-
citol caused a more rapid decrease in PTH 
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concentrations, and it appeared to be more 
eff ective than alfacalcidol in patients with 
lower baseline PTH levels. 
 Why is it that alfacalcidol, which is 
metabolized to 1  ,25(OH) 2 D 3 (calcitriol) 
within a few hours in ESRD patients, 10 
functions similarly to paricalcitol in such 
patients but calcitriol does not? Hansen 
 et al. 9 do not have a specifi c explanation for 
the similar PTH, calcium, and phosphorus 
profi le obtained with alfacalcidol in rela-
tion to paricalcitol. Studies by others have 
shown that calcitriol and alfacalcidol bring 
about similar increments in serum 
1  ,25(OH) 2 D 3 when administered to 
ESRD patients, albeit when administered 
in slightly diff erent doses. 10 Clearly, pari-
calcitol is less hypercalcemic and hyper-
phosphatemic than calcitriol although 
equally eff ective in inhibiting PTH concen-
trations. 6 Decreased activity of paricalitol 
in the intestine and bone in relation to cal-
citriol has been postulated to account for 
the diff erence in the incidence of hypercal-
cemia and hyperphosphatemia. One pos-
sibility that should be considered is that the 
1  ,25(OH) 2 D 3 concentrations achieved in 
the study by Hansen  et al. 9 were lower than 
those achieved in studies in which calci-
triol was used. 7 Hansen and colleagues 9 
convincingly demonstrate that alfacalcidol 
administered over a 16-week period is as 
eff ective and safe as paricalcitol in control-
ling secondary hyperparathyroidism in 
ESRD and has a similar profi le with respect 
to changes in serum calcium and phospho-
rus. These findings are of considerable 
importance from an economic standpoint, 
as alfacalcidol is considerably cheaper than 
paricalcitol ( S 0.33 ( $ 0.46) for alfacalcidol 
versus  S 5.4 ( $ 7.6) for an equivalent dose of 
paricalcitol) in Europe. 
 Since the demonstration of the nega-
tive association of serum 1  ,25(OH) 2 D 
concentrations with plasma renin 11 
in the 1980s, and the subsequent demon-
stration of  renin gene inhibition by 
1  ,25(OH) 2 D 3 , 12 1  -hydroxylated vita-
min D analogs have been used, with 
mixed success, to reduce protein excretion 
in patients with diff erent types of renal 
disease through direct inhibition of  renin 
gene expression. 13,14 In the recently 
completed VITAL trial, paricalcitol was 
used to further inhibit proteinuria in 




























































 Figure 1  |  Metabolism of vitamin D 3 and alfacalcidol. The structure of paricalcitol is shown in the 
inset. 
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being treated with renin – angiotensin sys-
tem inhibitors. 13 Other than 1  -hydroxy-
lated analogs / metabolites, no other 
vitamin D compounds have been used to 
treat proteinuria. Is there any rationale for 
using vitamin D analogs other than 
1  ,25(OH) 2 D 3 or other 1  -hydroxylated 
metabolites? Clues from epidemiologic 
data suggest that there might be. In the US 
Third National Health and Nutrition 
Examination Survey (NHANES III) of 
approximately 15,000 participants, a step-
wise, statistically signifi cant, increase in 
the prevalence of albuminuria was 
observed with decreasing quartiles of 
serum 25-hydroxyvitamin D concentra-
tion. 15 Th erefore, there is some rationale 
for treating proteinuric subjects with pre-
cursors to 1  ,25(OH) 2 D. Th is hypothesis 
was tested by Kim  et al. , 16 who show in 
this issue of  Kidney International that the 
administration of vitamin D 3 (cholecalcif-
erol, the endogenous,  ‘ natural ’ precursor 
to all vitamin D 3 metabolites) to non-
smoking, vitamin D-insuffi  cient or vita-
min D-deficient subjects with type 2 
diabetes and proteinuria, already receiv-
ing therapy with renin – angiotensin sys-
tem-blocking drugs, reduces the urinary 
albumin – creatinine ratio at 2 and 4 
months following initiation of therapy. 
Th e decrease in the urinary albumin – cre-
atinine ratio is associated with a reduction 
in urinary excretion of the fi brogenic pro-
tein transforming growth factor-  1 (TGF-
  1). Sixty-three patients (average age 69 
years) with presumed diabetic nephropa-
thy (only fi ve had biopsy-proven diabetic 
nephropathy) in the context of long-
standing type 2 diabetes mellitus (average 
duration 17 years) and hypertension (94 % 
of patients had coexisting hypertension) 
were treated with varying doses of vitamin 
D 3 to increase their 25-hydroxyvitamin D 
concentrations to greater than 30 ng / ml. 
Most patients (41 / 49) had estimated 
glomerular filtration rates of 30 – 89 
ml / min. Urinary albumin – creatinine, mono-
cyte chemoattractant protein-1 – creatinine, 
and TGF-  1 – creatinine ratios, serum 
vitamin D metabolites, and vitamin D-
binding protein, creatinine, calcium, and 
phosphorus concentrations were periodi-
cally measured. Following treatment, 
serum 25-hydroxyvitamin D and 1,25-
dihydroxyvitamin D increased in all 
patients. Th e estimated glomerular fi ltra-
tion rate did not change. Among non-
smokers the spot albumin – creatinine ratio 
decreased from 14.4  mg / mmol to 10.2 and 
9.3  mg / mmol at 2 and 4 months. No 
change in the urinary albumin – creatinine 
ratio was observed in smokers. Th e uri-
nary TGF-  1 – creatinine ratio decreased 
in the non-smokers following cholecalcif-
erol treatment, whereas no such change 
was observed in the smokers. Th e urinary 
monocyte chemoattractant protein-1 – cre-
atinine ratio did not change in either 
group. Correlations between the  change in 
urinary albumin – creatinine ratios and the 
 change in urinary TGF-  1 – creatinine 
ratios are not reported. It is likely that 
cholecalciferol functions in this context by 
increasing serum 1  ,25(OH) 2 D 3 , which in 
turn inhibits TGF-  1 synthesis. Whether 
the effect of vitamin D 3 administrat-
ion, concomitant increases in serum 
1  ,25(OH) 2 D 3 , and the resultant changes 
in proteinuria can be attributed to reduced 
renin expression remains to be elucidated. 
 Th e subjects treated in the trial reported 
by Kim  et al. 16 and those treated in the 
VITAL trial 13 had very similar and low 25-
hydroxyvitamin D serum concentrations at 
the beginning of the trial (mean 25-hydrox-
yvitamin D  =  18.4 ng / ml in the Kim  et al. 
trial and   16.8  ng / ml ( ~ 42  nmol / l) in the 
VITAL trial). It is relevant to ask whether 
the subjects in the VITAL trial might have 
responded equally well to the natural pre-
cursor vitamin D metabolite vitamin D 3 
(cholecalciferol), and at much lower cost 
(see relevant costs above; cholecalciferol is 
considerably cheaper than alfacalcidol). 
Th ere are several diff erences between results 
obtained with cholecalciferol repletion in 
the Kim  et al. trial 16 and paricalcitol therapy 
given in the context of the VITAL trial that 
may provide clues into diff erent mecha-
nisms of action of the two drugs. First, 
cholecalciferol therapy does not appear to 
be associated with a change in blood pres-
sure, whereas subjects treated with 2   g 
paricalcitol (the eff ective antiproteinuric 
dose) in the VITAL trial had a decrease in 
their systolic blood pressure. Whether this 
means that paricalcitol is more eff ective than 
cholecalciferol in inhibiting  renin gene 
expression remains to be determined. Sec-
ond, non-smoking subjects treated 
with cholecalciferol who showed changes in 
protein excretion had reductions in pro-
teinuria without changes in the estimated 
glomerular fi ltration rate. Patients treated 
with the eff ective antiproteinuric dose of 
2   g paricalcitol in the VITAL trial showed 
significant reductions in the estimated 
glomerular filtration rate. This may also 
point to a more robust eff ect of paricalcitol 
(compared with cholecalciferol) on the 
renin – angiotensin system. Th ese fi ndings 
regarding changes, or lack thereof, in the 
estimated glomerular fi ltration rate should 
be viewed with caution, because estimated 
glomerular fi ltration rate calculations deter-
mined on the basis of serum creatinine do 
not necessarily refl ect the true glomerular 
fi ltration 17 and do not take into account 
changes in creatinine production or tubular 
creatinine excretion that may occur follow-
ing drug treatment. Indeed, in this issue of 
 Kidney International , Agarwal  et al. 18 dem-
onstrate that following paricalcitol treat-
ment, serum creatinine increases, but this 
increase in serum creatinine is associated 
with an increase in the urinary excretion of 
creatinine, and therefore glomerular fi ltra-
tion rate remains unchanged when assessed 
by creatinine clearance and, independently, 
by iothalamate clearance. Th ird, in the trial 
with cholecalciferol reported by Kim  et al. , 16 
only non-smokers appeared to have a ben-
efi cial eff ect when treated with cholecalcif-
erol. Th e smoking status of subjects and 
their response to paricalcitol are not 
reported in the VITAL trial. Although small 
and non-randomized, the study by Kim  et 
al. 16 does make the important point that 
repletion with cholecalciferol may be ben-
efi cial in non-smoking subjects with pre-
sumed diabetic nephropathy. Clearly, large 
trials with cholecalciferol given in amounts 
suffi  cient to increase 25-hydroxyvitamin D 
concentrations to 30  ng / ml are warranted. 
In the meantime, clinicians should treat dia-
betics with low 25-hydroxyvitamin D con-
centrations with vitamin D 3 to raise serum 
25-hydroxy vitamin D to at least 30  ng / ml. 
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 Ischemic preconditioning is an innate 
tissue adaptation induced by ischemia or 
toxic insult that confers both local 
and remote organ protection against 
subsequent exposure to the same or other 
injury. Local ischemic preconditioning was 
fi rst observed in dogs as the limitation of 
myocardial infarct size produced by a series 
of brief (4 × 5  min) circumfl ex artery occlu-
sions and reperfusions before a more 
sustained occlusion of the same artery. 1 
Later studies identifi ed the existence of 
remote ischemic preconditioning (RIPC), 
where transient ischemia of many organs 
and tissues, including heart, kidney, small 
bowel, liver, and skeletal muscle, induced 
systemic multiorgan protection against 
subsequent extended ischemia – reper-
fusion injury. 2,3 Ischemic preconditioning 
is highly conserved across species. 2 RIPC 
suggests the involvement of humoral medi-
ators, and many experiments demonstrate 
that protection is dialyzable, transferable, 
and receptor-mediated. 2,3 Th e observation 
that upper- or lower-limb ischemia 
induced by infl ation of a blood pressure 
cuff  provided myocardial protection in the 
absence of known adverse risks, and that 
protection could occur aft er initiation of 
injury (postconditioning), off ers a tantaliz-
ing, cheap, and easily applicable strategy 
for the prevention of acute kidney injury 
(AKI) in high-risk patients, provided that 
real clinical benefi ts are reproducible. 
Classically, local ischemic precondition-
ing induces immediate (early) protection, 
which wanes aft er a few hours. Early protec-
tion is followed by a delayed phase of pro-
tection that appears about 12 – 24  h aft er the 
inducing stimulus. Delayed protection is 
weaker but usually persists for days. 2,3 RIPC 
induces similar early and late protection, 
and both types of preconditioning occur 
largely through modulation of the response 
to reperfusion. Nevertheless, there are 
mechanistic diff erences between local and 
remote preconditioning, 2 and the details of 
signal transduction and eff ectiveness vary 
among species and the type of stimulus. 
Various humoral factors, including adeno-
sine, bradykinin, and cannabinoids, may be 
involved, and subcellular modulators such 
as nuclear factor- κ B and nitric oxide appear 
to be involved ( Figure 1 ). 2 – 4 Interestingly, 
preconditioning appears to require intact 
innervation of the preconditioning organ 
but not the target organ. Similarly, early and 
late ischemic preconditioning diff er in the 
relative importance of mediators, signal 
transduction pathways, and end eff ectors. 
Th e fi nal common pathway appears to be a 
cascade of intracellular kinases with 
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